Cyclo Therapeutics, Inc. 8-K Report: Key Financial Insights & Updates

Based on the provided XML section of the financial report, here are the key insights and information extracted:

1. Entity Information:

• Company Name: Cyclo Therapeutics, Inc.
• CIK Number: 0000922247
• IRS Number: 59-3029743
• Address: 6714 NW 16th Street, Suite B, Gainesville, FL 32653
• Phone Number: 386-418-8060

2. Filing Information:

• Filing Type: 8-K (Current Report)
• Filing Date: September 21, 2023
• SEC File Number: 000-25466

3. Stock Information:

• Common Stock Par Value: $0.0001 per share
• Ticker Symbol for Common Stock: CYTH (NASDAQ)
• Warrants to Purchase Common Stock: Identified with the ticker symbol CYTHW (NASDAQ)

4. Financial Reporting Context:

• The context for the financial reporting is explicitly defined (start and end date both being September 21, 2023).
• It includes dimensions for the classes of stock, specifically addressing common stock and warrants.

5. XBRL Information:

• The document adheres to the XBRL (eXtensible Business Reporting Language) format, which is a standardized way to prepare financial statements.
• It references specific namespaces for US GAAP and other relevant XBRL standards.

Summary Insights:

• Cyclo Therapeutics, Inc. filed an 8-K report on September 21, 2023, indicating potentially significant or material events that investors should be aware of.
• The company has both common stock and warrants listed on NASDAQ, which could indicate active trading and investment interest in the firm.
• The financial reporting complies with XBRL standards, ensuring transparency and consistency in reporting.

These insights can be useful for investors, analysts, and stakeholders monitoring the company's financial health and compliance with SEC regulations.